Showing 1651-1660 of 2235 results for "".
- BIOCORNEUM® Expands Product Line With New Bruise, Scar Recovery Solutionshttps://modernaesthetics.com/news/biocorneum-expands-product-line-with-new-bruise-scar-recovery-solutions/2484030/BIOCORNEUM® unveiled new additions to its recovery line during Plastic Surgery The Meeting, held October 9–12 in New Orleans. The brand introduced its new Bruise Care System, featuring a topical cream and an oral supplement designed for patients und
- PLADUOpro Plasma System Debuts in North Americahttps://modernaesthetics.com/news/pladuopro-plasma-system-debuts-in-north-america/2483995/Aesthetic Management Partners (AMP) announced the North American launch of PLADUOpro, a dual-gas plasma device designed to support noninvasive skin resurfacing and regeneration. The device, which integrates both argon and nitro
- SkinMedica Updates Packaging, Launches New HA5 Moisturizerhttps://modernaesthetics.com/news/skinmedica-updates-packaging-launches-new-ha5-moisturizer/2483916/Allergan Aesthetics, a division of AbbVie, announced a comprehensive redesign of its SkinMedica® product packaging aimed at improving user experience and reducing environmental impact. The updated packaging includes a modernized logo, copper accents, and simplified
- Registration Open for 2026 Octane Aesthetics Tech Forumhttps://modernaesthetics.com/news/registration-open-for-2026-octane-aesthetics-tech-forum/2483870/Aesthetic executives, leading physicians, and entrepreneurs will dive into the latest trends and technology in aesthetic medicine at the 2026 Octane Aesthetics Tech Forum. The 2-day forum will be held January 8-9 at the Pendry in Newport Beach, California. The agenda includes sessions on
- CollPlant Advances Light-Activated Regenerative Filler Toward Clinical Trialshttps://modernaesthetics.com/news/collplant-advances-light-activated-regenerative-filler-toward-clinical-trials/2483589/CollPlant Biotechnologies has announced the completion of a nonclinical program supporting the development of its photocurable dermal filler, which combines hyaluronic acid with a modified form of recombinant human collagen (rhCollagen). The company plans to advanc
- Sofwave Ultrasound Technology Remodels Collagen, Elastin, and Hyaluronic Acid in the Skinhttps://modernaesthetics.com/news/sofwave-ultrasound-technology-remodels-collagen-elastin-and-hyaluronic-acid-in-the-skin/2483484/Sofwave’s ultrasound technology is a noninvasive treatment designed to lift sagging skin on the face and neck, improve laxity on the upper arms, and reduce fine lines and wrinkles. It can also address acne scars and the short-term appearance of cellulite. The company hosted an event in New York C
- Sciton Launches Multi-Wavelength Resurfacing Laser Platformhttps://modernaesthetics.com/news/sciton-launches-multi-wavelength-resurfacing-laser-platform/2483427/Sciton, Inc. has introduced HALO® TRIBRID™, a laser platform that integrates 3 wavelengths—2940 nm, 1927 nm, and 1470 nm—into a single resurfacing device. The system combines the company’s previously distinct technologies (HALO®, MOXI™, and Erbium Resurfacing) into one handpiece, allowing provide
- Hugel Marks 15 Years of Letybo with 2025 H.E.L.F Symposium in Seoulhttps://modernaesthetics.com/news/hugel-marks-15-years-of-letybo-with-2025-helf-symposium-in-seoul/2483385/More than 220 medical professionals from across the globe gathered in Seoul on September 14 for Hugel Inc.’s 2025 H.E.L.F. symposium, marking 15 years since the launch of its botulinum toxin, Letybo. The Hugel Expert Leader’s Forum was held at Seoul Dragon City under the theme, “K-Beau
- Neuvian Skincare Granted US Patent for Dual-Peptide Complexhttps://modernaesthetics.com/news/neuvian-skincare-granted-us-patent-for-dual-peptide-complex/2483373/Neuvian Skincare has received a US patent for its dual-peptide formulation targeting inflammatory skin conditions such as wounds, scars, and eczema, according to a press release. The patent (No. 12,377,156 B2), issued for “Compositions and Methods for Treatment of Wounds and Inflammatory Skin Con
- New HA Filler Obagi® saypha® MagIQ™ Approved by FDAhttps://modernaesthetics.com/news/new-ha-filler-obagi-saypha-magiq-approved-by-fda/2483329/The US Food and Drug Administration (FDA) has approved Obagi® saypha® MagIQ™, an injectable hyaluronic acid (HA) gel, marking the first product in the Obagi® saypha® collection under the Obagi Medical brand, Waldencast plc announced.